{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:16:09Z","timestamp":1783138569214,"version":"3.54.6"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Hospital","doi-asserted-by":"publisher","award":["KMUH104-4M50"],"award-info":[{"award-number":["KMUH104-4M50"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Hospital","doi-asserted-by":"publisher","award":["KMUH105-5M46"],"award-info":[{"award-number":["KMUH105-5M46"]}],"id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jfma.2026.05.067","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:34:50Z","timestamp":1779449690000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["SGLT2 inhibitors and geriatric syndromes in older adults with type 2 diabetes: A real-world cohort study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8475-5205","authenticated-orcid":false,"given":"Chun-Ying","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7318-5152","authenticated-orcid":false,"given":"Tzu-Jung","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hao","family":"Jen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan-Chih","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Shiuan","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2026.05.067_bib1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2026.05.067_bib2","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2026.05.067_bib3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2026.05.067_bib4","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2026.05.067_bib5","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afad254","article-title":"Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis","volume":"53","author":"Aldafas","year":"2024","journal-title":"Age Ageing"},{"key":"10.1016\/j.jfma.2026.05.067_bib6","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/ageing\/afz096","article-title":"Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME\u00ae trial","volume":"48","author":"Monteiro","year":"2019","journal-title":"Age Ageing"},{"key":"10.1016\/j.jfma.2026.05.067_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101419","article-title":"Efficacy and safety profile of SGLT2 inhibitors in the elderly: how is the benefit\/risk balance?","volume":"49","author":"Scheen","year":"2023","journal-title":"Diabetes & metabolism"},{"key":"10.1016\/j.jfma.2026.05.067_bib8","article-title":"Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jfma.2026.05.067_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13102828","article-title":"Unexpectedly rapid onset of severe sarcopenia in an elderly diabetic man following SGLT2i administration: a case report","volume":"13","author":"Czarnecka","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jfma.2026.05.067_bib10","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.clnu.2023.10.004","article-title":"Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: a controversy that must be solved","volume":"42","author":"Afsar","year":"2023","journal-title":"Clinical nutrition (Edinburgh, Scotland)"},{"key":"10.1016\/j.jfma.2026.05.067_bib11","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1532-5415.2007.01156.x","article-title":"Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept","volume":"55","author":"Inouye","year":"2007","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jfma.2026.05.067_bib12","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afac201","article-title":"The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus","volume":"51","author":"Evans","year":"2022","journal-title":"Age Ageing"},{"key":"10.1016\/j.jfma.2026.05.067_bib13","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"10.1016\/j.jfma.2026.05.067_bib14","article-title":"Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study","volume":"386","author":"Shin","year":"2024","journal-title":"BMJ (Clinical research ed)"},{"key":"10.1016\/j.jfma.2026.05.067_bib15","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1111\/jgs.18306","article-title":"Newer glucose-lowering drugs and risk of dementia: a systematic review and meta-analysis of observational studies","volume":"71","author":"Tang","year":"2023","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jfma.2026.05.067_bib16","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209805","article-title":"SGLT2 inhibitor use and risk of dementia and parkinson disease among patients with type 2 diabetes","volume":"103","author":"Kim","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.jfma.2026.05.067_bib17","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.amjmed.2024.06.030","article-title":"Association between SGLT2 inhibitors and risk of dementia and Parkinson's Disease: a meta-analysis of 12 randomized controlled trials","volume":"137","author":"Jaiswal","year":"2024","journal-title":"Am J Med"},{"key":"10.1016\/j.jfma.2026.05.067_bib18","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2337\/dci19-0074","article-title":"SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a State of fasting mimicry: a paradigm shift in understanding their mechanism of action","volume":"43","author":"Packer","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2026.05.067_bib19","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1111\/dom.13814","article-title":"Sodium-glucose co-transporter inhibitors: medications that mimic fasting for cardiovascular prevention","volume":"21","author":"Giaccari","year":"2019","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.jfma.2026.05.067_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.992937","article-title":"Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis","volume":"13","author":"Yang","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.jfma.2026.05.067_bib21","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3390\/neurolint16060124","article-title":"New insights into the role of SGLT-2 inhibitors in the prevention of dementia","volume":"16","author":"Hung","year":"2024","journal-title":"Neurol Int"},{"key":"10.1016\/j.jfma.2026.05.067_bib22","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2337\/dc25-0433","article-title":"SGLT2is versus metformin for delirium prevention in type 2 diabetes: a Real-World, Head- to-Head comparative Study","volume":"48","author":"Sun","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2026.05.067_bib23","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/jama.2017.12067","article-title":"Delirium in older persons: advances in diagnosis and treatment","volume":"318","author":"Oh","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2026.05.067_bib24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41582-022-00698-7","article-title":"The inter-relationship between delirium and dementia: the importance of delirium prevention","volume":"18","author":"Fong","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.jfma.2026.05.067_bib25","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2147\/CLEP.S536542","article-title":"Sodium-Glucose cotransporter 2 inhibitors and lower risk of depression in population with type 2 diabetes mellitus: a population-based active comparator, new-user design","volume":"17","author":"Kao","year":"2025","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.jfma.2026.05.067_bib26","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00592-023-02063-6","article-title":"Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong","volume":"60","author":"Mui","year":"2023","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.jfma.2026.05.067_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2023.114448","article-title":"Dapagliflozin inhibits the activity of lateral habenula to alleviate diabetes mellitus-induced depressive-like behavior","volume":"366","author":"Dong","year":"2023","journal-title":"Exp Neurol"},{"key":"10.1016\/j.jfma.2026.05.067_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112319","article-title":"Biphasic effects of SGLT-2 inhibitors on sleep quality in older people with type 2 diabetes: a longitudinal analysis","volume":"226","author":"Yavuz Veizi","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jfma.2026.05.067_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13061474","article-title":"Effects of SGLT2 inhibitors on sleep apnea parameters and cheyne-stokes respiration in patients with acute decompensated heart failure: a prospective cohort Study","volume":"13","author":"Kalaydzhiev","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.jfma.2026.05.067_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/clc.70190","article-title":"Can sodium-glucose Co-Transporter-2 inhibitors improve sleep quality, anxiety, and quality of life in patients with heart failure?","volume":"48","author":"Erbay","year":"2025","journal-title":"Clin Cardiol"},{"issue":"1","key":"10.1016\/j.jfma.2026.05.067_bib31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2337\/dc25-1031","article-title":"Sodium-Glucose Cotransporter-2 inhibitors, Glucagon-Like Peptide-1 receptor agonists, and frailty progression in older adults with type 2 diabetes","volume":"49","author":"Park","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2026.05.067_bib32","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1007\/s00125-024-06190-9","article-title":"Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach","volume":"67","author":"G\u00fcdemann","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.jfma.2026.05.067_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1245642","article-title":"Sodium-glucose cotransporter-2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis","volume":"14","author":"Mascolo","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jfma.2026.05.067_bib34","doi-asserted-by":"crossref","first-page":"9178","DOI":"10.1038\/s41598-025-91101-0","article-title":"Longitudinal association of SGLT2 inhibitors and GLP-1RAs on falls in persons with type 2 diabetes","volume":"15","author":"Suzuki","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2026.05.067_bib35","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s41999-023-00752-7","article-title":"SGLT2 inhibitors and falls in older heart failure patients: to prescribe or to deprescribe? A clinical review","volume":"14","author":"van Poelgeest","year":"2023","journal-title":"European geriatric medicine"},{"key":"10.1016\/j.jfma.2026.05.067_bib36","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s13300-023-01481-7","article-title":"The effects of sodium-glucose cotransporter 2 inhibitors on body composition in type 2 diabetes mellitus: a narrative review","volume":"14","author":"Jahangiri","year":"2023","journal-title":"Diabetes therapy : research, treatment and education of diabetes and related disorders"},{"key":"10.1016\/j.jfma.2026.05.067_bib37","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1007\/s11255-025-04625-9","article-title":"SGLT2 inhibitors do not cause de novo urinary incontinence in diabetic female patients with chronic kidney disease","volume":"57","author":"Helvac\u0131","year":"2025","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.jfma.2026.05.067_bib38","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11892-016-0789-4","article-title":"SGLT2 inhibitors: benefit\/risk balance","volume":"16","author":"Scheen","year":"2016","journal-title":"Curr Diabetes Rep"},{"key":"10.1016\/j.jfma.2026.05.067_bib39","doi-asserted-by":"crossref","first-page":"S277","DOI":"10.2337\/dc26-S013","article-title":"Older adults: standards of care in Diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jfma.2026.05.067_bib40","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.125.012794","article-title":"Efficacy and safety of SGLT2 inhibitors in heart failure: observational evidence in geriatric Patients-AGING-HF","volume":"18","author":"Hacil","year":"2025","journal-title":"Circulation Heart failure"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664626005656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664626005656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T03:20:41Z","timestamp":1783135241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664626005656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":40,"alternative-id":["S0929664626005656"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2026.05.067","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 inhibitors and geriatric syndromes in older adults with type 2 diabetes: A real-world cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2026.05.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2026, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}